02754nas a2200229   4500000000100000008004100001260001500042100002500057700002900082700002600111700003200137700002800169700003000197700002900227700002800256245008000284856003800364300001200402490000800414520208800422022001402510       2024                            d  c2024-06-101 aAna Ubago-Rodríguez1 aMaría I. Quiñones-Vico1 aManuel Sánchez-Díaz1 aRaquel Sanabria-de la Torre1 aÁlvaro Sierra-Sánchez1 aTrinidad Montero-Vílchez1 aAna Fernández-González1 aSalvador Arias-Santiago00aChallenges in Psoriasis Research: A Systematic Review of Preclinical Models  uhttps://doi.org/10.1159/000538993  a620-6520 v2403 aIntroduction: Psoriasis is a chronic inflammatory skin disease with variable clinical presentation, multifactorial etiology and an immunogenetic basis. Several studies demonstrate that it results from a dysregulated interaction between skin keratinocytes, immune cells, and the environment that leads to a persistent inflammatory process modulated by cytokines and T cells. The development of new treatment options requires increased understanding of pathogenesis. However, the successful implementation of effective drugs requires well-characterized and highly available preclinical models that allow researchers to quickly and reproducibly determine their safety and efficacy. Methods: A systematic search on PubMed and Scopus databases was performed and assessed to find appropriate articles about psoriasis models applying the key words previously defined. The PRISMA guidelines were employed. Results: A total of 45 original articles were selected that met the selection criteria. Among these, there are articles on in vivo, in vitro, and ex vivo models, with the in vitro model being the majority due to its ease of use. Within animal models, the most widely used in recent years are chemically induced models using a compound known as imiquimod. However, the rest of the animal models used throughout the disease’s research were also discussed. On the other hand, in vitro models were divided into two and three dimensions. The latter were the most used due to their similarity to human skin. Lastly, the ex vivo models were discussed, although they were the least used due to their difficulty in obtaining them. Conclusions: Therefore, this review summarizes the current preclinical models (in vivo, in vitro, and ex vivo), discussing how to develop them, their advantages, limitations, and applications. There are many challenges to improve the development of the different models. However, research in these in vitro model studies could reduce the use of animals. This is favored with the use of future technologies such as 3D bioprinting or organ-on-a-chip technologies.  a1018-8665